As the events that unfolded in Washington on Jan. 6 captured the nation’s attention, the raging coronavirus pandemic claimed its highest U.S. death toll yet, killing more than 4,000 people in a single day according to a Reuters tally.

Scientists at the National Institutes of Health and Moderna Inc. may take about two months to determine whether doses of the company’s Covid-19 vaccine can be halved to double the supply of the shots in the U.S., according to the agency.

The U.S. Food and Drug Administration warned health care personnel not to make any changes to the dosing of Covid-19 vaccines and that doing so would place the public health at risk and undermine “the historic vaccination effort to protect the population.”

As Operation Warp Speed – the Trump administration’s program to develop and distribute a Covid-19 vaccine – struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.

The Covid-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April 2021, the chief adviser for the U.S. Covid-19 vaccine program said.

Operation Warp Speed – the Trump administration’s program to accelerate Covid-19 vaccine development and distribution – succeeded on the development component, but is failing in the early stages of distribution.

The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.

A vaccine being developed by the Nanovaccine Institute at Iowa State University (ISU) will be able to be administered without needles and in one dose.

Millions of Covid-19 vaccines were sitting unused in U.S. hospitals and elsewhere a week into the massive inoculation campaign, putting the government’s target for 20 million vaccinations during December in doubt.

The first injections of Moderna’s Covid-19 vaccine started to be administered on Dec. 21 after the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) on Dec. 18.